Sugi Predict

Sugi Predict / Targets / ADAMTS13

ADAMTS13

A disintegrin and metalloproteinase with thrombospondin motifs 13 · Q76LX8 · ADAMTS13 on Sugi Atlas →

7 patent compounds predicted against ADAMTS13, 6 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL19280489 SCHEMBL19280489 0.53 2/20
SCHEMBL19782984 SCHEMBL19782984 0.52 1/20
SCHEMBL19783018 SCHEMBL19783018 0.50 1/20
SCHEMBL16735375 SCHEMBL16735375 0.47 1/20
SCHEMBL28014404 SCHEMBL28014404 0.47 1/20
SCHEMBL5664372 SCHEMBL5664372 0.42 1/20

Clinical trials — most relevant to ADAMTS13 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura PHASE4WITHDRAWN
Aspirin for Prophylaxis of TTP PHASE2/PHASE3NOT_YET_RECRUITING
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura PHASE3ACTIVE_NOT_RECRUITING
The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) PHASE2COMPLETED
Therapeutic Plasma Exchange in Septic Shock: A Pilot Study PHASE2RECRUITING
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) PHASE2COMPLETED
Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP) PHASE1COMPLETED
ADAMTS-13 LEVEL AS PREDICTIVE BIOMARKER FOR DEVELOPMENT OF PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS (ADAPTHRO) nanUNKNOWN
A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI) nanUNKNOWN
Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura nanACTIVE_NOT_RECRUITING
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome) nanRECRUITING
ADAMTS13 in Thrombotic Thrombocytopenic Purpura nanCOMPLETED
A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI) nanUNKNOWN
Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP) nanAPPROVED_FOR_MARKETING
TTP and aHUS in Complicated Pregnancies nanUNKNOWN
Screening of TMA Patients für ADAMTS13 Activity (Adamscreen) nanUNKNOWN
A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program nanNOT_YET_RECRUITING
A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura nanRECRUITING
Coagulation Monitoring in Patients on Extracorporeal Membrane Oxygenation (Observational Study) nanUNKNOWN
Re-evaluation of Some Old Rheumatoid Arthritis Therapy: A Randomized Controlled Trial nanCOMPLETED
The United Kingdom Thrombotic Thrombocytopenic Purpura Registry (UK TTP Registry) nanUNKNOWN
Immunological Aspect of Thrombotic Thrombocytopenic Purpura (TTP) nanRECRUITING
Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura nanRECRUITING
Role of A Disintegrin and Metalloproteinase (ADAM) in Epithelial Dysfunction nanCOMPLETED
A Prospective Investigation of the VWF-ADAMTS 13 Axis in Acute Ischaemic Brain Injury (TIAs and Stroke). nanUNKNOWN
Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer nanRECRUITING
Combined Hemoperfusion and Therapeutic Plasma Exchange for Treatment of Patients With Septic Shock nanCOMPLETED
Italian iTTP Registry nanRECRUITING
Exercise-related Irisin on Inflammation and Pain nanUNKNOWN
Apoptotic Changes in Gingiva Caused by Smoking nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ADAMTS13 binder may also engage these)

ProteinNameSimilarity
Q769J6 — 0.995 Q769J6 →
Q70UZ7 — 0.989 Q70UZ7 →
O95428 — 0.987 O95428 →
D3ZTE0 — 0.987 D3ZTE0 →
P98167 — 0.986 P98167 →
Q80YC5 — 0.985 Q80YC5 →
P98140 — 0.985 P98140 →
Q4G0T1 — 0.985 Q4G0T1 →
Q9R1A3 — 0.985 Q9R1A3 →
Q8BYG9 — 0.985 Q8BYG9 →
O97507 — 0.985 O97507 →
Q5GFL6 — 0.984 Q5GFL6 →
Q9EPX2 — 0.984 Q9EPX2 →
Q9H324 — 0.984 Q9H324 →
P58459 — 0.984 P58459 →
P0C0K6 — 0.983 P0C0K6 →
Q7TQH7 — 0.983 Q7TQH7 →
Q8CG65 — 0.983 Q8CG65 →
Q96NZ8 — 0.982 Q96NZ8 →
P0C0K7 — 0.982 P0C0K7 →
INSRR Insulin receptor-related protein 0.982 landscape →
TMPRSS6 Transmembrane protease serine 6 0.982 landscape →
Q6ZRI0 — 0.982 Q6ZRI0 →
F12 Coagulation factor XII 0.982 landscape →
Q8R0S6 — 0.982 Q8R0S6 →
P00744 — 0.981 P00744 →
Q80YA8 — 0.981 Q80YA8 →
P0C5J5 — 0.981 P0C5J5 →
Q499S5 — 0.981 Q499S5 →
Q9H239 — 0.981 Q9H239 →